Literature DB >> 25691567

Antigenicity and immunogenicity of a trimeric envelope protein from an Indian clade C HIV-1 isolate.

Rangasamy Sneha Priya1, Menon Veena2, Irene Kalisz2, Stephen Whitney2, Dhopeshwarkar Priyanka2, Celia C LaBranche3, Mullapudi Sri Teja1, David C Montefiori3, Ranajit Pal2, Sundarasamy Mahalingam4, Vaniambadi S Kalyanaraman2.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) isolates from India mainly belong to clade C and are quite distinct from clade C isolates from Africa in terms of their phylogenetic makeup, serotype, and sensitivity to known human broadly neutralizing monoclonal antibodies. Because many of these properties are associated with the envelope proteins of HIV-1, it is of interest to study the envelope proteins of Indian clade C isolates as part of the ongoing efforts to develop a vaccine against HIV-1. To this end, we purified trimeric uncleaved gp145 of a CCR5 tropic Indian clade C HIV-1 (93IN101) from the conditioned medium of 293 cells. The purified protein was shown to be properly folded with stable structure by circular dichroism. Conformational integrity was further demonstrated by its high affinity binding to soluble CD4, CD4 binding site antibodies such as b12 and VRC01, quaternary epitope-specific antibody PG9, and CD4-induced epitope-specific antibody 17b. Sera from rabbits immunized with gp145 elicited high titer antibodies to various domains of gp120 and neutralized a broad spectrum of clade B and clade C HIV-1 isolates. Similar to other clade B and clade C envelope immunogens, most of the Tier 1 neutralizing activity could be absorbed with the V3-specific peptide. Subsequent boosting of these rabbits with a clade B HIV-1 Bal gp145 resulted in an expanded breadth of neutralization of HIV-1 isolates. The present study strongly supports the inclusion of envelopes from Indian isolates in a future mixture of HIV-1 vaccines.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  AIDS; Antigen; Cell Surface Protein; Human Immunodeficiency Virus (HIV); Vaccine Development

Mesh:

Substances:

Year:  2015        PMID: 25691567      PMCID: PMC4423705          DOI: 10.1074/jbc.M114.621185

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  66 in total

1.  An infectious DNA clone of HIV type 1 subtype C.

Authors:  N Mochizuki; N Otsuka; K Matsuo; T Shiino; A Kojima; T Kurata; K Sakai; N Yamamoto; S Isomura; T N Dhole; Y Takebe; M Matsuda; M Tatsumi
Journal:  AIDS Res Hum Retroviruses       Date:  1999-09-20       Impact factor: 2.205

2.  Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.

Authors:  George Sellhorn; Zane Kraft; Zachary Caldwell; Katharine Ellingson; Christine Mineart; Michael S Seaman; David C Montefiori; Eliza Lagerquist; Leonidas Stamatatos
Journal:  J Virol       Date:  2011-10-26       Impact factor: 5.103

3.  Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization.

Authors:  Florian Klein; Ron Diskin; Johannes F Scheid; Christian Gaebler; Hugo Mouquet; Ivelin S Georgiev; Marie Pancera; Tongqing Zhou; Reha-Baris Incesu; Brooks Zhongzheng Fu; Priyanthi N P Gnanapragasam; Thiago Y Oliveira; Michael S Seaman; Peter D Kwong; Pamela J Bjorkman; Michel C Nussenzweig
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

4.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

Authors:  Punnee Pitisuttithum; Peter Gilbert; Marc Gurwith; William Heyward; Michael Martin; Fritz van Griensven; Dale Hu; Jordan W Tappero; Kachit Choopanya
Journal:  J Infect Dis       Date:  2006-11-03       Impact factor: 5.226

5.  Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16.

Authors:  Thaddeus M Davenport; Della Friend; Katharine Ellingson; Hengyu Xu; Zachary Caldwell; George Sellhorn; Zane Kraft; Roland K Strong; Leonidas Stamatatos
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

6.  Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.

Authors:  E J Platt; K Wehrly; S E Kuhmann; B Chesebro; D Kabat
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

7.  Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization.

Authors:  A Buchacher; R Predl; K Strutzenberger; W Steinfellner; A Trkola; M Purtscher; G Gruber; C Tauer; F Steindl; A Jungbauer
Journal:  AIDS Res Hum Retroviruses       Date:  1994-04       Impact factor: 2.205

8.  Increasing the potency and breadth of an HIV antibody by using structure-based rational design.

Authors:  Ron Diskin; Johannes F Scheid; Paola M Marcovecchio; Anthony P West; Florian Klein; Han Gao; Priyanthi N P Gnanapragasam; Alexander Abadir; Michael S Seaman; Michel C Nussenzweig; Pamela J Bjorkman
Journal:  Science       Date:  2011-10-27       Impact factor: 47.728

9.  Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers.

Authors:  Ilja Bontjer; Mark Melchers; Tommy Tong; Thijs van Montfort; Dirk Eggink; David Montefiori; William C Olson; John P Moore; James M Binley; Ben Berkhout; Rogier W Sanders
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240

10.  A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.

Authors:  Rogier W Sanders; Ronald Derking; Albert Cupo; Jean-Philippe Julien; Anila Yasmeen; Natalia de Val; Helen J Kim; Claudia Blattner; Alba Torrents de la Peña; Jacob Korzun; Michael Golabek; Kevin de Los Reyes; Thomas J Ketas; Marit J van Gils; C Richter King; Ian A Wilson; Andrew B Ward; P J Klasse; John P Moore
Journal:  PLoS Pathog       Date:  2013-09-19       Impact factor: 6.823

View more
  7 in total

1.  DNA prime/protein boost vaccination elicits robust humoral response in rhesus macaques using oligomeric simian immunodeficiency virus envelope and Advax delta inulin adjuvant.

Authors:  Veena Menon; Victor I Ayala; Sneha P Rangaswamy; Irene Kalisz; Stephen Whitney; Lindsey Galmin; Asma Ashraf; Celia LaBranche; David Montefiori; Nikolai Petrovsky; Vaniambadi S Kalyanaraman; Ranajit Pal
Journal:  J Gen Virol       Date:  2017-07-31       Impact factor: 3.891

2.  Structure-based Design of Cyclically Permuted HIV-1 gp120 Trimers That Elicit Neutralizing Antibodies.

Authors:  Sannula Kesavardhana; Raksha Das; Michael Citron; Rohini Datta; Linda Ecto; Nonavinakere Seetharam Srilatha; Daniel DiStefano; Ryan Swoyer; Joseph G Joyce; Somnath Dutta; Celia C LaBranche; David C Montefiori; Jessica A Flynn; Raghavan Varadarajan
Journal:  J Biol Chem       Date:  2016-11-22       Impact factor: 5.157

3.  Enhanced Immune Responses to HIV-1 Envelope Elicited by a Vaccine Regimen Consisting of Priming with Newcastle Disease Virus Expressing HIV gp160 and Boosting with gp120 and SOSIP gp140 Proteins.

Authors:  Sunil K Khattar; Anthony L DeVico; Celia C LaBranche; Aruna Panda; David C Montefiori; Siba K Samal
Journal:  J Virol       Date:  2015-11-18       Impact factor: 5.103

4.  Evolution of Neutralization Response in HIV-1 Subtype C-Infected Individuals Exhibiting Broad Cross-Clade Neutralization of HIV-1 Strains.

Authors:  Narayanaiah Cheedarla; Babu Hemalatha; Brahmaiah Anangi; Kannan Muthuramalingam; Murugesan Selvachithiram; Pattabiraman Sathyamurthi; Nandagopal Kailasam; Raghavan Varadarajan; Soumya Swaminathan; Srikanth Prasad Tripathy; S Kalyanaraman Vaniambadi; D Ramanathan Vadakkupattu; Luke Elizabeth Hanna
Journal:  Front Immunol       Date:  2018-03-27       Impact factor: 7.561

5.  The adjuvant AlhydroGel elicits higher antibody titres than AddaVax when combined with HIV-1 subtype C gp140 from CAP256.

Authors:  Michiel T van Diepen; Rosamund Chapman; Penny L Moore; Emmanuel Margolin; Tandile Hermanus; Lynn Morris; Phindile Ximba; Edward P Rybicki; Anna-Lise Williamson
Journal:  PLoS One       Date:  2018-12-17       Impact factor: 3.240

6.  Cross Type Neutralizing Antibodies Detected in a Unique HIV-2 Infected Individual From India.

Authors:  K K Vidyavijayan; Narayanaiah Cheedarala; Hemalatha Babu; Lucia K Precilla; Pattabiraman Sathyamurthi; Padmapriyadarsini Chandrasekaran; Kailapuri G Murugavel; Soumya Swaminathan; Srikanth P Tripathy; Luke Elizabeth Hanna
Journal:  Front Immunol       Date:  2018-12-17       Impact factor: 7.561

7.  Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals.

Authors:  Narayanaiah Cheedarla; K Lucia Precilla; Hemalatha Babu; K K Vidya Vijayan; Manickam Ashokkumar; Padmapriyadarsini Chandrasekaran; Nandagopal Kailasam; Jagadish Chandrabose Sundaramurthi; Soumya Swaminathan; Viswanath Buddolla; S Kalyanaraman Vaniambadi; V D Ramanathan; Luke Elizabeth Hanna
Journal:  Sci Rep       Date:  2017-04-24       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.